Atezolizumab Consolidation Impresses in High-Risk DLBCL

Published Date: 17 Jun 2024

Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation?

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

2.

Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL

3.

The importance of breast cancer screening

4.

Many Americans unaware of links between HPV and cancers, poll reveals

5.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot